Immunotherapy

The Parker Institute for Cancer Immunotherapy awarded nearly $3 million worth of grants to six early career researchers.

Ute Dugan, MD, PhD, has been appointed senior vice president for clinical research at Parker Institute for Cancer Immunotherapy.

A single 14-day course of the monoclonal antibody teplizumab had lasting effects on delay of type 1 diabetes diagnosis and improved beta-cell function for high-risk individuals, according to new data.

The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent’s manufacturer.

Pathological response should be an early surrogate endpoint for clinical trials of neoadjuvant therapy for melanoma, according to results of a pooled analysis published in Nature Medicine.

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.

Christian Hinrichs, MD, has been appointed chief of the section of cancer immunotherapy at Rutgers Cancer Institute of New Jersey.

Since 2014, when we took the helm of HemOnc Today as joint Chief Medical Editors, the overall progress in oncology has been spectacular.

In this video, Nancy U. Lin, MD, discussed abstracts in immunotherapy presented at the San Antonio Breast Cancer Symposium 2020.

The San Antonio Breast Cancer Symposium and American Association for Cancer Research will honor two breast cancer researchers for their contributions to the field.